In August 2020, Eppendorf AG had Conducted a Virtual Lab Exhibition for biotechnology Instruments and Consumables

 

Since many of the major market competitors are creating and introducing new solutions to increase their market share, technological advancements have made it simpler to produce equipment for cell and gene therapies. The market for cell and gene therapy thawing equipment has also expanded due to rising healthcare costs in developed and developing nations. Due to the rise in chronic diseases and technological development, the market for cell and gene therapy thawing equipment is expanding.  

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-cell-and-gene-therapy-thawing-equipment-market

Global cell and gene therapy thawing equipment market is expected to reach USD 1,771.29 million by 2028 from USD 643.23 million in 2020, growing with a healthy CAGR of 14.2% in the forecast period of 2021 to 2028. The rising incidence of chronic diseases drives the market for cell and gene therapy equipment. The need for cell and gene therapy thawing equipment declines because of an increase in the cost of cell and gene therapy engineering, limiting the market's expansion. The market for thawing equipment for cell and gene therapy is presented with an opportunity by the surge in fresh technical development. The lack of accessibility in low- and middle-income nations presents a problem for the market expansion for cell and gene therapy thawing equipment, though.   

cell and gene therapy thawing equipment market

Increase in cases of genetic diseases such as cystic fibrosis and sickle cell anemia will drive the market's growth rate

According to the Center of Disease Control and Prevention (CDC) and Cystic Fibrosis Foundation data, around 30,000 Americans, 3000 Americans and 20, 000 Europeans are with cystic fibrosis. According to the National Center for Biotechnology Information, U.S. data, the incidence of cystic fibrosis in Europe ranged from 1 in 1,353 in Ireland to 1 in 25,000 in Finland. In Australia, the incidence is well proven and is on average 1 in 3,000. In Canada, the incidence is 1 in 3,300 and 1 in 4,000 in the U.S. due to the presence of large ethnical variations. This is driving the growth of the market. Increased expenditure by public and private players on infrastructure development will also promote the market growth rate. Continuous research and development pertaining to the deployment of advanced technologies will yet again widen the scope of growth.  

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2021 to 2028

Base Year

2020

Historic Years

2019 (Customizable to 2013 - 2018)

Quantitative Units

Revenue in USD Thousand, Volumes in Units, Pricing in USD

Segments Covered

Modality (Benchtop and Portable), Sample (Cell Therapies and Gene Therapies), Type (Manual Thawing System and Automatic Thawing System), Application (Upstream Processing and Downstream Processing), End User (Blood Banks And Transfusion Centers, Hospitals and Diagnostic Laboratories, Research Laboratories And Academic Institutes, Biotechnology and Pharmaceutical Industry, Cord Blood and Stem Cell Banks, Gene Banks and Others), Distribution Channel (Direct Tender, Third Part Distributor and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Pluristem Therapeutics Inc. (Israel), Genesis BPS (U.S.), Eppendorf AG (Germany), Cytiva (U.S.), Glenmark Pharmaceutical Inc., (U.S.), EDGE pharma (India), Cook (U.K.), SARSTEDT AG & Co. KG (Germany), Barkey (Germany), Boekel Scientific (U.S.), LABCOLD (U.K.), Sartorious AG (Germany) and Helmer Scientific Inc. (U.S.) among others.             

Data Points Covered in the Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, import/export analysis, pricing analysis, production consumption analysis, and pestle analysis.

Segment Analysis:

Global cell and gene therapy thawing equipment market is categorized into six notable segments which are based on the modality, sample, type, application, end user, distribution channel.

  • On the basis of modality, the global cell and gene therapy thawing equipment market is segmented into benchtop and portable. In 2021, the benchtop segment is expected to dominate the market with 80.58% market share due to rising technological advancement in Cell and gene therapy thawing equipment.
  • On the basis of sample, the global cell and gene therapy thawing equipment market is segmented into cell therapies and gene therapies. In 2021, the cell therapies segment is expected to dominate the market with 82.44% market share due to rising prevalence and incidence of cancer.
  • On the basis of type, the global cell and gene therapy thawing equipment market is segmented into manual thawing system and automatic thawing system. In 2021, the automatic thawing system segment is expected to dominate the market with 79.73% market share as it improves reproducibility and minimizes human error.
  • On the basis of application, the global cell and gene therapy thawing equipment market is segmented into upstream processing and downstream processing. In 2021, the upstream processing segment is expected to dominate the market with 74.81% market share due to rising technological advancements in the thawing systems.
  • On the basis of end user, the global cell and gene therapy thawing equipment market is segmented into blood banks and transfusion centers, hospitals and diagnostic laboratories, research laboratories and academic institutes, biotechnology and pharmaceutical industry, cord blood and stem cell banks, gene banks and others. In 2021, the hospitals and diagnostic laboratories segment is expected to dominate the market with 34.87% due to the number of blood banks and advanced healthcare providers in low and middle income countries.

The hospitals and diagnostic laboratories segment will dominate the end-user segment of the cell and gene therapy thawing equipment market

The hospitals and diagnostic laboratories segment will emerge as the dominating segment under end-user segment in 2021. This is because of the growing number of hospitals and diagnostic laboratories all over the globe. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.

  • On the basis of distribution channel, the global cell and gene therapy thawing equipment market is segmented into direct tender, third part distributor and others. In 2021, the direct tender segment is expected to dominate the market with a 69.01% market share as most healthcare providers procured cell and gene therapy thawing equipment right from direct tender.

The direct tender segment will dominate the distribution channel segment of the cell and gene therapy thawing equipment market

The direct tender blends segment will emerge as the dominating segment under distribution channel in 2021 with approximately 70% market share. This is because of the growing number of distribution channels and players in the market especially in the developing economies. Further, growth and expansion of the transportation industry all around the globe will further bolster the growth of this segment.

Major Players              

Data Bridge Market Research recognizes the following companies as the market players in cell and gene therapy thawing equipment market: Pluristem Therapeutics Inc. (Israel), Genesis BPS (U.S.), Eppendorf AG (Germany), Cytiva (U.S.), Glenmark Pharmaceutical Inc., (U.S.), EDGE pharma (India), Cook (U.K.), SARSTEDT AG & Co. KG (Germany), Barkey (Germany), Boekel Scientific (U.S.), LABCOLD (U.K.), Sartorious AG (Germany) and Helmer Scientific Inc. (U.S.).

cell and gene therapy thawing equipment market

Market Development

  • In November 2020, Eppendorg AG launched the SmartBlock for Cell Thawing in India. The Smart Block Cell Thawing is a foundation for downstream processing. It is easy and convenient for scientists for further use in every cell handling lab
  • In August 2020, Eppendorf AG conducted a virtual lab exhibition for biotechnology instruments and consumables. It would result in increased awareness about the use of thawing instruments
  • Lonza (Switzerland) and IsoPlexis (US) joined forces in 2020 to create the next-generation of precision cell therapy manufacturing.
  • Danaher purchased the Biopharma business from General Electric Company's Life Sciences division in 2020. Danaher is a biopharmaceutical company. The acquisition resulted in the creation of Cytiva, a brand-new firm that operates independently under Danaher's Life Sciences division.
  • Thermo Fisher Scientific spent USD 24 million at its Inchinnan (Scotland) facility in 2019 to increase its large-volume liquid manufacturing capacity for cell culture media and to enhance its worldwide bioproduction capabilities.

Regional Analysis

Geographically, the countries covered in the cell and gene therapy thawing equipment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in cell and gene therapy thawing equipment market during the forecast period 2021 - 2028

North America is anticipated to account for a sizable portion of the global market during the forecast period. This is due to the considerable new product development operations carried out by well-known firms in this area. One of the main potential growth elements thought to be responsible for the increased prevalence of chronic diseases in this area is the clinical urgency to use these items. The rising prevalence of CVD, rising healthcare costs, rising disposable income, rising healthcare awareness, and the availability of technologically advanced gadgets in the area are all factors that contribute to this market segment's sizeable share.

Asia-Pacific is estimated to be the fastest-growing region in cell and gene therapy thawing equipment market the forecast period 2021 - 2028

Over the forecast period, Asia-Pacific is anticipated to increase at a profitable pace. The significant growth is linked to rising healthcare costs. The regional market is growing as a result of increasing physician awareness of the advantages of these products, which include low dosage requirements, timed medication release, direct device-centered infection mitigation using anti-infective medication in combination, and reduced systemic exposure. High R&D expenditures by key competitors in the global market and an increase in the commercialization of these systems are the two main market drivers.

COVID-19 Impact

The market for cell treatment technologies is anticipated to be just little or barely impacted by the COVID-19 outbreak. The demand for an effective COVID medicine or vaccine that could aid in lessening the severity of cases has increased as COVID rates have increased. Cell-based research is a crucial stage in the production of vaccines, which might aid in the market's expansion. The supply chain experienced disruption in the early months of the COVID outbreak, which caused the clinical studies to be postponed. This can have some unfavorable effects on the market. For instance, clinical trial delays have been reported by biopharmaceutical corporations, including significant players like Pfizer and Eli Lilly.

For more detailed information about the cell and gene therapy thawing equipment on market report, click here – https://www.databridgemarketresearch.com/reports/global-cell-and-gene-therapy-thawing-equipment-market